The estimation of a preference-based single index for the IBS-QoL by mapping to the EQ-5D-5L in patients with irritable bowel syndrome
-
Published:2021-09-21
Issue:
Volume:
Page:
-
ISSN:0962-9343
-
Container-title:Quality of Life Research
-
language:en
-
Short-container-title:Qual Life Res
Author:
Sturkenboom RoselORCID, Keszthelyi Daniel, Brandts Lloyd, Weerts Zsa Zsa R. M., Snijkers Johanna T. W., Masclee Ad A. M., Essers Brigitte A. B.
Abstract
Abstract
Purpose
The Irritable Bowel Syndrome Quality of Life (IBS-QoL) questionnaire is a commonly used and validated IBS-specific QoL instrument. However, this questionnaire is in contrast to the EQ-5D-5L, not preference-based and as such does not allow calculation of QALYs. The objective of this study was to describe the convergent- and known-group validity of both questionnaires and to develop a mapping algorithm from EQ-5D-5L which enable IBS-QoL scores to be transformed into utility scores for use in economic evaluations.
Methods
We used data from two multicenter randomized clinical trials, which represented the estimation and external validation dataset. The convergent validity was investigated by examining correlations between the EQ-5D-5L and IBS-QoL and the known-group validity by calculating effect sizes. Ordinary least squares (OLS), censored least absolute deviations (CLAD), and mixture models were used in this mapping approach.
Results
283 IBS patients were included (n = 189 vs. n = 84). Mean IBS-QoL score was 71.13 (SD 15.66) and mean EQ-5D-5L utility score was 0.73 (SD 0.19). The overall sensitivity of the IBS-QoL and EQ-5D-5L to discriminate between patient and disease characteristics was similar. CLAD model 4, containing the total IBS-QoL score and squared IBS-SSS (IBS severity scoring system), was chosen as the most appropriate model to transform IBS-QoL scores into EQ-5D-5L utility scores.
Conclusion
This study reports the development of an algorithm where the condition-specific questionnaire IBS-QoL can be used to calculate utility values for use in economic evaluations. Including a clinical measure, IBS-SSS, in the model improved the performance of the algorithm.
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health
Reference63 articles.
1. Palsson, O. S., Whitehead, W., Törnblom, H., Sperber, A. D., & Simren, M. (2020). Prevalence of Rome IV functional bowel disorders among adults in the United States, Canada, and the United Kingdom. Gastroenterology, 158, 1262-1273.e3. 2. Canavan, C., West, J., & Card, T. (2014). Review article: The economic impact of the irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 40, 1023–1034. 3. Spiegel, B., Harris, L., Lucak, S., Mayer, E., Naliboff, B., Bolus, R., et al. (2009). Developing valid and reliable health utilities in irritable bowel syndrome: Results from the IBS PROOF cohort. American Journal of Gastroenterology, 104, 1984–1991. 4. Ford, A. C., Moayyedi, P., Chey, W. D., Harris, L. A., Lacy, B. E., Saito, Y. A., et al. (2018). American college of gastroenterology monograph on management of irritable bowel syndrome. American Journal of Gastroenterology, 113, 1–18. 5. Lacy, B. E., Pimentel, M., Brenner, D. M., Chey, W. D., Keefer, L. A., Long, M. D., et al. (2021). ACG clinical guideline: Management of irritable bowel syndrome. The American Journal of Gastroenterology, 116, 17–44.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|